Aims and Scope
BioDrugs is a peer-reviewed pharmacology journal. BioDrugs covers the development and therapeutic application of biotechnology-based pharmaceuticals and diagnostic products for the treatment of human disease. It has a 2020 impact factor of 5.807. It is published by Adis International (SpringerNature).
Key Metrics
10.5
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
0.001 - 0.005
Eigenfactor
Eigenfactor
Eigenfactor Score measures the number of times articles from the journal published in the past five years have been cited. This does not include self citations.
5 - 10
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
76
H index
H-Index
Journal's h-index reflects the collective citation impact of the authors publishing in the journal. The h-index is defined as the maximum value of h such that the given journal has published at least h papers that have each been cited at least h times.
0.9
5-Year SI
5-year SI
- N/A 2-year SI
- 0.92 Lifetime SI
Scite Index
Scite Index
scite Index is the ratio of citations supporting research which is published in the journal to sum of citations either supporting or contrasting the research published in the journal for the same time period. Minimum 100 supporting citations required.
Q1
Pharmacology
SJR
- Q1 Pharmacology
- Q1 Biotechnology
- Q1 Pharmacology (medical)
- Q1 Medicine (miscellaneous)
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
1.74
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
Indexed in the following public directories
-
Web of Science -
Scopus -
SJR
Topics Covered
- Cancer
- Bevacizumab
- Infliximab
- Synthetic drugs
- Adalimumab
- Clinical trial
- Immunotherapy
- Systematic review
- Breast cancer
- Rituximab
- Objective response
- Chimeric antigen receptor
- Multiple sclerosis
- Confidence interval
- Biosimilar
- Antibody-drug conjugate
- Filgrastim
- Etanercept
- Epoetin alpha
- Trastuzumab
Journal Specifications
| Overview | |
| Publisher | ADIS INT LTD |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 1994 |
| Publisher URL | Visit website |
| Website URL | Visit website |
Planning to publish in BioDrugs ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
Discovery of Therapeutic Antibodies Targeting Complex Multi-Spanning Membrane Proteins.
- 25 Oct 24
- BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
-
Full paper
Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review.
- 17 Oct 24
- BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
-
Full paper
Real-World Comparative Analysis of Trastuzumab Originator and Biosimilars: Safety, Efficacy, and Cost Effectiveness.
- 16 Oct 24
- BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
-
Full paper
Advanced Therapy Medicinal Products: Availability, Access and Expenditure in Italy.
- 15 Oct 24
- BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
-
Full paper
Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic Dermatitis.
- 15 Oct 24
- BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
-
Full paper
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab.
- 30 Sep 24
- BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Scite analysis
Powered by scite_
1.6k articles received 26.2k citations see all
- 473 Supporting
- 24,957 Mentioning
- 39 Contrasting
Editorial notices
- 0 Retractions
- 0 Withdrawals
- 20 Corrections
- 24 Errata
- 0 Expression of Concern
FAQs
How long has BioDrugs been actively publishing?
BioDrugs has been in operation since 1994 till date.
What is the publishing frequency of BioDrugs ?
BioDrugs published with a Bi-monthly frequency.
How many articles did BioDrugs publish last years ?
In 2023, BioDrugs published 66 articles.
What is the eISSN & pISSN for BioDrugs ?
For BioDrugs,eISSN is 1179-190X and pISSN is1173-8804.
What is Citescore for BioDrugs ?
Citescore for BioDrugs is 10.5.
What is H index for BioDrugs ?
H index for BioDrugs is 76.
What is SNIP score for BioDrugs ?
SNIP score for BioDrugs is 1.74.
What is the SJR for BioDrugs ?
SJR for BioDrugs is Q1.
Who is the publisher of BioDrugs ?
ADIS INT LTD is the publisher of BioDrugs.